European Free-to-Air TV Platforms Endorse Intertrust ExpressPlay XCA for Broadcast Content Protection
13.9.2018 15:00:00 EEST | Business Wire | Press release
Free-to-air TV platforms Freesat and Tivù have today endorsed Intertrust’s ExpressPlay XCA™ conditional access system (CAS) at IBC.
As the inventor of Digital Rights Management (DRM) technology, Intertrust introduced ExpressPlay XCA (XCA), a modern CAS that is based on their popular open standard Marlin technology, which was originally founded by Intertrust, Panasonic, Philips, Sony, and Samsung. ExpressPlay XCA leverages hardware security in smart TV and set-top box chipsets to provide world-class content security and full CAS capabilities – including head-end integration at a fraction of the cost of a legacy CAS.
“For years, TV operators have had to manage a tricky balance between set-top box manufacturers and CAS providers to deliver premium TV, often leaving themselves at the mercy of CAS vendors. Meanwhile broadband TV providers use easy-to-integrate DRM with far less overhead,” said Talal G. Shamoon, Intertrust’s chief executive officer. “With today’s TV chipsets, smart TVs and set-top boxes, we can remove legacy problems with our Marlin DRM-based XCA while reducing costs and time-to-market, and increasing choice.”
With increasing competition from the Internet, traditional TV operators are embracing economies of scale provided by modern technology. In response to smart TV manufacturers readily integrating DRM systems into their OTT stack, Intertrust created XCA to provide broadcasters with a simple way to reduce their costs.
“As Freesat expands its connected product range, we sought a cost efficient, open alternative to traditional CAS,” said Andy Carr Director of CE @ Freesat. “XCA provides us with industry approved content security across a broad range of devices. As our service continues to grow, Intertrust becomes a key partner for us protecting the best possible high-value entertainment experience for our customers.”
To protect and manage content, XCA technology is used in TV platforms across Europe, India, China, Japan, and the United States. Its advanced DRM software engine efficiently protects broadcast streams, resulting in a future proof, open technology that is flexible and cost effective.
“Our viewers are the most important element in the equation,” said Alberto Sigismondi, Tivù chief executive officer. “With XCA, we could provide our viewers with a range of content choice across traditional TV platforms and set-top boxes, but also bridge the gap between the interests of Italy’s broadcasters.”
Intertrust also announced at IBC that Vestel, Europe’s second largest TV manufacturer will incorporate XCA into their smart TVs. Vestel joins a growing community of device makers who support Marlin-based technologies around the world.
About Intertrust
Intertrust provides trusted computing products and services to leading global corporations – from mobile, CE and IoT manufacturers, to service providers, and enterprise software platform companies. These products include the world’s leading digital rights management (DRM), software tamper resistance, and technologies to enable private data exchanges for various verticals including energy, entertainment, retail/marketing, automotive, fintech, and IoT.
Founded in 1990, Intertrust is headquartered in Silicon Valley with regional offices in London, Tokyo, Mumbai, Bangalore, Hyderabad, Beijing, Seoul, Riga, and Tallinn. The Company has a legacy of invention, and its fundamental contributions in the areas of computer security and digital trust are globally recognized. Intertrust holds hundreds of patents that are key to Internet security, trust, and privacy management components of operating systems, trusted mobile code and networked operating environments, web services, and cloud computing.
Additional information is available at intertrust.com, or follow us on Twitter or LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180913005407/en/
Contact information
Intertrust Technologies Corporation
Nishtha Sharma, +91 981-932-6284
nishthas@intertrust.com
or
Actual
Agency
Brian Regan, +1 908-399-7161
brian.regan@actual.agency
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 10:00:00 EEST | Press release
SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter timeframes. The MoU underscores growing market adoption of SWISSto12’s HummingLink payload technology that leverages 3D-printing, with more than 2,000 pr
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 10:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly effective oral therapies that also address the diverse and often challenging manifestations of psoriasis, including involvement of high-impact sites like the scalp,” said Andy Plump, M.D., Ph.D., president of R&D at Takeda. “Our Phase 3 data demonstrated rapid and durable skin clearance across various patient types and in high-impact and hard-to-treat areas. Based on the results across nearly 3,000 patients, zaso
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 10:00:00 EEST | Press release
According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, today announced the launch of Luna 8, its next-generation hardware security module. Designed for the transition to post-quantum cryptography, Luna 8 enables organizations to securely store, protect, and manage cryptographic keys with market-leading performance, scalability, and speed. As organizations face growing pressure from emerging quantum threats, expanding AI workloads and evolving stringent regulatory requirements, Luna 8 provides the performance, security and cryp
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 08:00:00 EEST | Press release
Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participants. This allows those platforms to interoperate with traditional Link-16 platfor
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 08:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom